Bicara Therapeutics Q3 2026 loss widens to $71.2M
Bicara expects its existing cash, cash equivalents and marketable securities to fund operations into the first half of 2029.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Bicara Therapeutics Inc. reported third-quarter 2026 results and substantial enrollment in its FORTIFI-HN01 pivotal trial for first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma. Bicara expects topline results from an interim analysis in mid-2027. It is also enrolling patients in FORTIFI-FLEX, which compares two ficerafusp alfa dosing regimens, each combined with pembrolizumab; results are expected by the time of a potential U.S. approval in this indication.
Cash, cash equivalents and marketable securities were $442.3 million as of September 30, 2026, compared with $414.8 million as of December 31, 2025. Based on current operating and development plans, Bicara expects these resources to fund operations into the first half of 2029. Third-quarter research and development expenses were $56.5 million versus $33.0 million a year earlier, and general and administrative expenses were $19.2 million versus $7.7 million. Net loss was $71.2 million, or $1.04 per share, compared with $36.3 million, or $0.67 per share, in third-quarter 2025.
0 points · 0 major0 major · 1 point
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Moderate pointQuarterly net loss reached $71.2 million, versus $36.3 million a year earlier.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Cash, cash equivalents and marketable securities: $442.3 million
Research and development expenses: $56.5 million
General and administrative expenses: $19.2 million
+2 more
5 metrics
Cash, cash equivalents and marketable securities
$442.3 million
As of September 30, 2026; $414.8 million as of December 31, 2025
Research and development expenses
$56.5 million
Third quarter 2026; $33.0 million in third quarter 2025
General and administrative expenses
$19.2 million
Third quarter 2026; $7.7 million in third quarter 2025
Net loss
$71.2 million
Third quarter 2026; $36.3 million in third quarter 2025
Net loss per share
($1.04) per share
Basic and diluted, third quarter 2026; ($0.67) per share in third quarter 2025
Key Terms
pivotal trial, interim analysis, HNSCC, TGF-β ligand trap
4 terms
pivotal trial medical
"FORTIFI-HN01 pivotal trial"
A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.
interim analysis technical
"topline results from an interim analysis in mid-2027"
An interim analysis is an early review of a project or process before it is fully completed. For investors, it provides a snapshot of progress or performance, helping to identify whether things are on track, need adjustment, or should be stopped early. Think of it as a progress report that can influence decisions before the final outcome is known.
HNSCC medical
"head and neck squamous cell carcinoma (HNSCC)"
HNSCC stands for head and neck squamous cell carcinoma, a type of cancer that starts in the flat lining cells that cover the surfaces of the mouth, throat and related structures. It matters to investors because treatments, clinical trial results, regulatory approvals or changes in diagnosis rates can directly affect the commercial prospects and valuation of companies developing therapies or diagnostics for this disease—think of it as a market signal tied to demand for specific medical products.
TGF-β ligand trap medical
"a human transforming growth factor beta (TGF-β) ligand trap"
Earnings Snapshot
Research and development expenses: $56.5 million · Guidance included
Third quarter 2026
Research and development expenses
$56.5 million
Compared with $33.0 million in third quarter 2025
General and administrative expenses
$19.2 million
Compared with $7.7 million in third quarter 2025
Net loss
$71.2 million
Compared with $36.3 million in third quarter 2025
Net loss per share
($1.04) per share
Compared with ($0.67) per share in third quarter 2025
Guidance
Based on its current operating and development plans, Bicara expects its existing cash, cash equivalents and marketable securities to fund operations into the first half of 2029.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much cash did BCAX report, and how long is its runway?
Bicara reported $442.3 million in cash, cash equivalents and marketable securities as of September 30, 2026. Based on its current operating and development plans, the company expects these resources to fund operations into the first half of 2029.
When are BCAX's FORTIFI-HN01 interim results expected?
Bicara expects topline results from an interim analysis of the FORTIFI-HN01 pivotal trial in mid-2027. The trial is in first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma.
What dosing regimens is BCAX testing in FORTIFI-FLEX?
The study compares ficerafusp alfa given as a 12-week loading dose of 1500mg weekly followed by maintenance dosing of 2250mg every three weeks, with 1500mg weekly. Each regimen is combined with pembrolizumab.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 9, 2026
___________________________________
(Exact name of registrant as specified in its charter)
___________________________________
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||
(Address of principal executive offices and zip code) | ||||||||
( | ||||||||
(Registrant's telephone number, including area code) | ||||||||
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 - Results of Operations and Financial Condition.
On November 9, 2026, Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and other business updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 - Financial Statements and Exhibits
(d) The following exhibits are being filed herewith:
Exhibit No. | Description | |||||||
99.1 | Press Release of Bicara Therapeutics Inc., dated November 9, 2026 | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 9th day of November, 2026.
Bicara Therapeutics Inc. | |||||
By: | /s/ Ryan Cohlhepp, Pharm.D | ||||
Name: | Ryan Cohlhepp | ||||
Title: | President, Interim Chief Executive Officer and Chief Operating Officer (Principal Executive Officer) | ||||
Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Achieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027
Enrolling FORTIFI-FLEX alternate dosing study; expect to have data by the time of potential U.S. approval in 1L R/M HPV-negative HNSCC
Company to host conference call and webcast today, November 9, 2026 at 8:30 a.m. ET
BOSTON, November 9, 2026 – Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the third quarter ended September 30, 2026 and provided a business update.
“Ficerafusp alfa was purpose-built for HPV-negative head and neck cancer by inhibiting both EGFR and TGF-β, and the depth and durability of response it has demonstrated to date continue to set it apart in a disease with significant unmet need,” said Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer of Bicara Therapeutics. “Achieving substantial enrollment in the FORTIFI-HN01 pivotal trial reflects strong execution by our team and growing recognition among investigators that HPV-negative disease requires a targeted approach grounded in its distinct biology. As we advance toward our planned interim analysis, our focus is twofold: moving with speed and aiming for ficerafusp alfa to enter the market with a competitive profile that gives physicians, patients, and payers a clear reason to choose it. At the same time, we are evaluating less-frequent dosing through FORTIFI-FLEX, which has the potential to further enhance ficerafusp alfa’s profile. With our commercial leadership team now in place, we are well-positioned as we continue to prepare to bring ficerafusp alfa to patients.”
Third Quarter 2026 Highlights and Recent Progress
Ficerafusp Alfa in 1L R/M HPV-Negative HNSCC
•Achieved substantial enrollment in the FORTIFI-HN01 pivotal trial in first-line (1L) recurrent or metastatic (R/M) human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), to enable topline results from an interim analysis in mid-2027.
•Continue to enroll FORTIFI-FLEX, a randomized, open-label clinical trial that is evaluating ficerafusp alfa, administered as a 12-week loading dose of 1500mg weekly (QW) followed by maintenance dosing of 2250mg every three weeks (Q3W) as compared to 1500mg QW of ficerafusp alfa, each in combination with pembrolizumab. The company expects to have results from this study by the time of a potential U.S. approval in 1L R/M HPV-negative HNSCC.
Key Anticipated Upcoming Milestones
HNSCC
•Expect topline results from an interim analysis of the FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC in mid-2027.
Other Solid Tumors and Translational Data
•Present data from Phase 1b expansion cohort evaluating ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients with 3L+ mCRC (RAS/BRAF wild type MSS) in January 2027.
•Present preclinical data evaluating the effect of tumor-targeted TGF-β neutralization with ficerafusp alfa on fibrosis and drug penetration at the European Society for Medical Oncology (ESMO) Immuno-Oncology & Advanced Therapies Congress 2026, taking place December 14-16 in London, United Kingdom.
Third Quarter 2026 Financial Results
•Cash, Cash Equivalents and Marketable Securities: As of September 30, 2026, Bicara had cash, cash equivalents and marketable securities of $442.3 million, compared to $414.8 million in cash, cash equivalents and marketable securities as of December 31, 2025. Based on its current operating and development plans, the company expects that its existing cash, cash equivalents and marketable securities will fund operations into the first half of 2029.
•Research and Development Expenses: Research and development expenses were $56.5 million for the third quarter of 2026 as compared to $33.0 million for the third quarter of 2025. The increase was primarily due to costs associated with the ongoing FORTIFI-HN01 pivotal trial, FORTIFI-FLEX trial, Phase 1/1b dose expansion cohorts, and an increase in personnel costs.
•General and Administrative Expenses: General and administrative expenses were $19.2 million for the third quarter of 2026 as compared to $7.7 million for the third quarter of 2025. The increase was primarily due to additional personnel costs and professional fees associated with expanding the organization as the company advances its pivotal trial and prepares for potential commercialization.
•Net Loss: Net loss totaled $71.2 million for the third quarter of 2026 compared to $36.3 million for the third quarter of 2025.
Upcoming Investor Conferences
Bicara will participate in the following upcoming investor conferences:
•Stifel Healthcare Conference 2026 on November 11 at 9:20 a.m. ET
•Jefferies Global Healthcare Conference on November 16 at 12:00 p.m. GMT
•Piper Sandler 38th Annual Healthcare Conference on December 2 at 8:30 a.m. ET
Live webcasts of the fireside chats will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. Replays of the webcasts will be archived and available for 30 days following each event.
Conference Call Information
Bicara will host a live conference call and webcast at 8:30 a.m. ET today to discuss third quarter 2026 financial results and business updates. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. An archived replay will also be available for 30 days following the event.
About Bicara Therapeutics
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the
tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all contain identifying words. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding Bicara’s strategy, business plans and focus, including the clinical development of ficerafusp alfa, including the FORTIFI-HN01 pivotal trial interim analysis readout in mid-2027, the FORTIFI-FLEX study to evaluate a loading and Q3W maintenance regimen with anticipated results by the time of a potential U.S. approval in 1L R/M HPV-negative HNSCC, and the expansion cohorts of Bicara’s Phase 1/1b trial of ficerafusp alfa and the timing of future data releases; the growing recognition among investigators of the distinct biology of HPV-negative HNSCC; the expected therapeutic potential and clinical benefits of ficerafusp alfa, including potential efficacy, depth, durability and tolerability; Bicara’s ability to scale and prepare for potential commercialization of ficerafusp alfa; the potential for U.S. regulatory approval and launch of ficerafusp alfa, including our aim for ficerafusp alfa to enter the market with a competitive profile; and Bicara’s expected operating expenses and capital expenditure requirements, including its cash runway into the first half of 2029. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks relating to Bicara’s research and development activities; Bicara’s ability to execute on its business plans and strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to the clinical development of ficerafusp alfa; the company’s dependence on third parties; risks related to the company’s financial condition and need for additional funds in order to commercialize ficerafusp alfa, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Bicara’s intellectual property protections; and risks related to the competitive landscape for ficerafusp alfa; as well as other risks described in “Risk Factors,” in Bicara’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Bicara’s subsequent filings with the U.S. Securities and Exchange Commission (SEC). In addition, any forward-looking statements represent Bicara’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Bicara intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
BICARA THERAPEUTICS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited, in thousands except shares and per share data)
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
Operating expenses | |||||||||||||||||||||||
Research and development | $ | 56,476 | $ | 32,975 | $ | 149,713 | $ | 92,106 | |||||||||||||||
General and administrative | 19,235 | 7,701 | 46,190 | 22,376 | |||||||||||||||||||
Total operating expenses1 | 75,711 | 40,676 | 195,903 | 114,482 | |||||||||||||||||||
Loss from operations | (75,711) | (40,676) | (195,903) | (114,482) | |||||||||||||||||||
Other income | |||||||||||||||||||||||
Interest income | 4,516 | 4,386 | 13,175 | 14,082 | |||||||||||||||||||
Total other income | 4,516 | 4,386 | 13,175 | 14,082 | |||||||||||||||||||
Net loss before income taxes | (71,195) | (36,290) | (182,728) | (100,400) | |||||||||||||||||||
Income tax expense | (54) | (40) | (168) | (164) | |||||||||||||||||||
Net loss | $ | (71,249) | $ | (36,330) | $ | (182,896) | $ | (100,564) | |||||||||||||||
Net Loss per share, basic and diluted | $ | (1.04) | $ | (0.67) | $ | (2.78) | $ | (1.84) | |||||||||||||||
Weighted-average number common shares outstanding, basic and diluted | 68,375,411 | 54,563,864 | 65,717,625 | 54,519,496 | |||||||||||||||||||
Other comprehensive loss | |||||||||||||||||||||||
Unrealized loss on marketable securities, net of tax | (1,301) | (136) | (2,112) | (136) | |||||||||||||||||||
Total other comprehensive loss | (1,301) | (136) | (2,112) | (136) | |||||||||||||||||||
Total comprehensive loss | $ | (72,550) | $ | (36,466) | $ | (185,008) | $ | (100,700) | |||||||||||||||
1 Expenses include the following non-cash stock-based compensation expense | |||||||||||||||||||||||
Research & Development | $ | 2,911 | $ | 1,384 | $ | 9,362 | $ | 3,684 | |||||||||||||||
General and administrative | 7,069 | 2,230 | 14,714 | 6,873 | |||||||||||||||||||
Total stock-based compensation expense | $ | 9,980 | $ | 3,614 | $ | 24,076 | $ | 10,557 | |||||||||||||||
BICARA THERAPEUTICS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands)
September 30, 2026 | December 31, 2025 | ||||||||||
Assets | |||||||||||
Current assets | |||||||||||
Cash and cash equivalents | $ | 82,021 | $ | 96,685 | |||||||
Prepaid expenses and other assets | 9,064 | 7,252 | |||||||||
Marketable securities | 360,325 | 318,116 | |||||||||
Total current assets | 451,410 | 422,053 | |||||||||
Property and equipment, net | 965 | 330 | |||||||||
Right of use asset – operating lease | 723 | 1,701 | |||||||||
Other assets | 7,544 | 6,910 | |||||||||
Total assets | $ | 460,642 | $ | 430,994 | |||||||
Liabilities and stockholders’ equity | |||||||||||
Current liabilities | |||||||||||
Accounts payable | $ | 2,979 | $ | 5,515 | |||||||
Accounts payable – related party | 658 | 2,278 | |||||||||
Accrued expenses and other current liabilities | 46,184 | 18,898 | |||||||||
Accrued expenses and other current liabilities – related party | 530 | 1,141 | |||||||||
Operating lease liability – current portion | 880 | 1,117 | |||||||||
Total current liabilities | 51,231 | 28,949 | |||||||||
Operating lease liability – net of current portion | — | 593 | |||||||||
Total liabilities | 51,231 | 29,542 | |||||||||
Total stockholders' equity | 409,411 | 401,452 | |||||||||
Total liabilities and stockholders’ equity | $ | 460,642 | $ | 430,994 | |||||||
Contacts
Investors
Rachel Frank
IR@bicara.com
Media
Tim Palmer
Tim.Palmer@bicara.com
Tim Palmer
Tim.Palmer@bicara.com